Federal Contractor Misconduct Database (FCMD)
Improper Marketing and Advertising of Risperdal and Invega – Multistate Settlement
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals reached a $181 million settlement with 37 states and the District of Columbia to resolve charges of improper marketing and advertising of the antipsychotic drugs Risperdal and Invega. The states alleged that from 1998 through at least 2004 Janssen engaged in deceptive and misleading practices when it marketed Risperdal, Risperdal Consta, Risperdal M-Tab, and Invega for off-label uses, and that Janssen concealed and misrepresented information regarding the side effects and efficacy of Risperdal.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement